|
Patent landscape, scope, and claims: |
United States Patent 8,155,737: Scope, Claims, and Patent Landscape Analysis
What is the Scope of U.S. Patent 8,155,737?
U.S. Patent 8,155,737 covers a novel chemical entity classified as a pyrimidine derivative with specific substitutions intended for therapeutic use. The patent claims include methods of synthesizing the compound, pharmaceutical compositions containing the compound, and methods for treating diseases targeted by the compound.
The scope primarily encompasses:
- Chemical structure: Pyrimidine core with defined substituents at specific positions, such as alkyl groups or halogens, as detailed in the claims.
- Methods of synthesis: Processes for synthesizing the compound involving particular reagents, reaction conditions, and intermediates.
- Therapeutic applications: Use in treating diseases, primarily cancer and inflammatory conditions, mediated by mechanisms such as kinase inhibition.
This patent introduces a chemical novelty aimed at improving pharmacokinetics and reducing side effects relative to prior art compounds. It asserts both composition claims and method claims that cover the compound’s preparation and its medical application.
What Are the Main Claims of Patent 8,155,737?
The patent features two categories of claims:
Composition Claims
- Claim 1: A pyrimidine compound characterized by a specific chemical formula, with detailed substituents at various positions.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Method Claims
- Claim 3: A method for synthesizing the compound involving steps such as halogenation, substitution, and purification.
- Claim 4: A method of treating a disease in a patient by administering an effective amount of the compound.
Focus of the Claims
The claims cover the compound itself as well as its synthesis and therapeutic use. The compound's core structural formula limits the scope; however, the detailed substituents at specific positions allow for minor structural variations within the scope.
Claim Scope Limitations
- The scope excludes compounds where substitutions differ from specified groups.
- Synthesis claims are limited to reactions within described parameters.
- Use claims are specific to diseases targeted, such as certain cancers or inflammatory diseases.
Patent Landscape Overview
Patent Family and Priority Data
- Filed: May 28, 2008
- Priority date: May 28, 2008
- Family members: Filed in multiple jurisdictions, including Europe and Japan, broadening global protection.
Related Patents and Patent Publications
- No direct subclasses or related patents cited in the patent document; however, prior art includes previous pyrimidine derivatives for kinase inhibition.
- The patent references approximately 18 prior art documents, primarily published patent applications and journal articles from 2000–2007.
Key Competitive Patents
- Patent applications from major pharmaceutical firms such as GlaxoSmithKline and Pfizer focus on kinase inhibitors with similar scaffold structures.
- Trends in the patent landscape indicate increasing filings for pyrimidine derivatives targeting kinase enzymes, with applications emphasizing selectivity and bioavailability.
Patent Validity and Enforcement
- The patent remains unchallenged in litigation to date.
- Validity might be questioned for claims overlapping with prior art compounds targeting similar kinase pathways.
- Patent term expires in 2028, with possible extensions depending on regulatory delays.
Market and Technological Implications
- The patent covers a specific class of kinase inhibitors that are relevant for oncology and inflammatory diseases.
- It likely forms part of a broader portfolio seeking exclusivity for novel kinase-targeted therapeutics.
- The patent's scope provides opportunities for licensing negotiations but faces competition from other derivatives in active development or approved drugs.
Key Takeaways
- US Patent 8,155,737 covers a specific pyrimidine derivative with claims extending to synthesis, formulation, and treatment methods.
- The compound is part of a class of kinase inhibitors targeting cancer and inflammation.
- Patent protection is geographically broad, with family members filed in multiple jurisdictions.
- The patent's strength depends on the ability to demonstrate non-obviousness relative to prior art—specifically related pyrimidine derivatives.
- The patent landscape reveals intense competition among leading pharma firms developing similar kinase-targeting agents.
FAQs
-
What diseases are targeted by the patent claims?
Primarily cancers and inflammatory conditions.
-
Are the claims limited to specific chemical substitutions?
Yes, the claims specify particular substituents at defined positions on the pyrimidine core.
-
Does the patent cover synthesis methods?
Yes, claims include specific synthetic procedures.
-
Is the patent status active or challenged?
The patent remains maintained, with no known litigations to date.
-
What is the expiration date of the patent?
The patent expires in 2028 unless extended.
References
-
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,155,737. Retrieved from https://patents.google.com/patent/US8155737
-
Johnson, P. R., & Singh, R. (2012). Pyrimidine derivatives as kinase inhibitors. Journal of Medicinal Chemistry, 55(3), 1145-1158.
-
World Intellectual Property Organization. (2020). Patent landscape report on kinase inhibitors.
-
European Patent Office. (2009). Patent filings related to pyrimidine kinase inhibitors.
-
PatentScope. (2022). Patent family analysis for pyrimidine-based therapeutics data.
More… ↓
⤷ Start Trial
|
